

REMARKS

Upon entry of this amendment, claims 28, 31, and 38-41 are pending, claim 41 having been newly added. Support for new claim 41 can be found in paragraph [0016].

Applicants would like to thank Examiner Haq for reaching out to Applicants regarding submitting a supplemental amendment. Examiner Haq has asked Applicants to provide a certified copy of the UK priority document. Applicants expect to receive a certified copy very shortly and will transmit it to the USPTO upon receipt.

CONCLUSION

It is respectfully submitted that the claims are in condition for allowance.

If there are any remaining issues or the Examiner believes that a telephone conference with the Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617)-871-8469.

Applicants believe that no fees are due with this filing. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936

/Christine McCormack/

Christine McCormack
Attorney for Applicant
Reg. No. 61,331

(617) 871-8486

Date: June 3, 2010